Result of Annual General Meeting
Source: RNS
27 June 2024
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Annual General Meeting
Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
|
Ordinary Resolutions |
Votes for |
% of votes cast for |
Votes Against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
|
1. To receive and adopt the Company's annual accounts for the year ended 31 December 2023. |
172,981,350 |
99.89 |
189,346 |
0.11 |
173,170,696 |
12.91 |
804,255 |
|
2. To approve the Directors' Remuneration Report which is set out in the 2023 Annual Report and Accounts. |
155,914,909 |
90.14 |
17,056,623 |
9.86 |
172,971,532 |
12.89 |
1,003,419 |
|
3. To re-appoint Sir Marc Feldmann as a Director of the Company. |
168,819,296 |
97.51 |
4,316,573 |
2.49 |
173,135,869 |
12.90 |
839,082 |
|
4. To re-appoint PKF Littlejohn LLP as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. |
156,805,252 |
99.10 |
1,429,684 |
0.90 |
158,234,936 |
11.79 |
15,740,015 |
|
5. To authorise the Audit Committee to agree the auditor's remuneration. |
157,329,629 |
90.99 |
15,576,903 |
9.01 |
172,906,532 |
12.89 |
1,068,419 |
|
6. To authorise the Directors to allot shares pursuant to section 551 of the Companies Act 2006. |
153,328,931 |
88.71 |
19,513,766 |
11.29 |
172,842,697 |
12.88 |
1,132,254 |
|
Special Resolutions |
Votes for |
% of votes cast for |
Votes against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
|
7. To disapply pre-emption rights under section 570 of the Companies Act 2006. |
152,661,902 |
88.30 |
20,235,808 |
11.70 |
172,897,710 |
12.89 |
1,077,241 |
|
8. To approve for calling of general meetings (other than AGMs) on 14 days' notice. |
172,081,747 |
99.38 |
1,080,015 |
0.62 |
173,161,762 |
12.91 |
813,189 |
(1) The Company's issued share capital ("ISC") on 25 June 2024, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,341,815,988 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
|
|
Peterhouse Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
